Topical ranibizumab as a treatment of corneal neovascularization

Cornea

Volumn 32, Issue 7, 2013, Pages 992-997

  Ferrari, Giulio ^a   Dastjerdi, Mohammad H ^a   Okanobo, Andre ^a   Cheng, Sheng Fu ^a   Amparo, Francisco ^a   Nallasamy, Nambi ^a   Dana, Reza ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Corneal neovascularization; Ranibizumab; VEGF

Indexed keywords

RANIBIZUMAB;

ADULT; ALLERGIC REACTION; ARTICLE; BLOOD VESSEL DIAMETER; CENTRAL CORNEAL THICKNESS; CLINICAL ARTICLE; CORNEA NEOVASCULARIZATION; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; EROSION; EYE MALFORMATION; EYE TOXICITY; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR HEMORRHAGE; INTRAOCULAR PRESSURE; KERATOPATHY; MALE; MEAN ARTERIAL PRESSURE; OCULAR BLOOD VESSEL; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM; UNITED STATES; VISUAL ACUITY;

ADMINISTRATION, TOPICAL; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD VESSELS; CORNEA; CORNEAL NEOVASCULARIZATION; FEMALE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84879089061     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3182775f8d     Document Type: Article

References (33)

1. Chang JH, Gabison EE, Kato T, et al. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-249.
2. Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006;104:264-302.
3. Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci. 1996;37: 2485-2494.
4. Maguire MG, Stark WJ, Gottsch JD, et al. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Ophthalmology. 1994;101:1536-1547.
5. Bremer F. [Origin of corticosteroid glaucoma]. Bull Soc Belge Ophtalmol. 2007;304:111-116.
6. Pillai CT, Dua HS, Hossain P. Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci. 2000;41:2148-2153.
7. Epstein RJ, Hendricks RL, Harris DM. Photodynamic therapy for corneal neovascularization. Cornea. 1991;10:424-432.
8. Sheppard JD, Epstein RJ, Lattanzio FA, et al. Argon laser photodynamic therapy of human corneal neovascularization after intravenous administration of dihematoporphrin ether. Am J Ophthalmol. 2006;141:524-529.
9. Brooks BJ, Ambati BK, Marcus DM, et al. Photodynamic therapy for corneal neovascularisation and lipid degeneration. Br J Ophthalmol. 2004;88:840.
10. Lyle WM, Cullen AP, Charman WN. Role of lasers in eye care. Optom Vis Sci. 1993;70:136-151.
11. Yoon KC, Im SK, Park HY. Recurrent herpes simplex keratitis after verteporfin photodynamic therapy for corneal neovascularization. Cornea. 2010;29:465-467.
12. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41:2514-2522.
13. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006;113:633. e1-4.
14. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372. e5.
15. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci. 2004;45: 2666-2673.
16. Dursun A, Arici MK, Dursun F, et al. Comparison of the effects of bevacizumab and ranibizumab injection on corneal angiogenesis in an alkali burn induced model Int J Ophthalmol. 2012;5:448-451.
17. Sener E, Yuksel N, Yildiz DK, et al. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model. Curr Eye Res. 2011 Nov;36:1005-1013.
18. Barakat MR, Kaiser PK. VEGF inhibitors for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs. 2009;18:637-646.
19. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol. 2009;127: 381-389.
20. Pieramici DJ, Rabena MD. Anti-VEGF therapy: comparison of current and future agents. Eye. 2008;22:1330-1336.
21. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina. 2006;26:279-284.
22. Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology. 2008;115:e33-e38.
23. Zaki AA, Farid SF. Subconjunctival bevacizumab for corneal neovascularization. Acta Ophthalmol. 2010;88:868-871.
24. Koenig Y, Bock F, Horn F, et al. Short-and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2009;247: 1375-1382.
25. Kim TI, Chung JL, Hong JP, et al. Bevacizumab application delays epithelial healing in rabbit cornea. Invest Ophthalmol Vis Sci. 2009;50: 4653-4659.
26. Yu CQ, Zhang M, Matis KI, et al. Vascular endothelial growth factor mediates corneal nerve repair. Invest Ophthalmol Vis Sci. 2008;49: 3870-3878.
27. Mandalos A, Tsakpinis D, Karayannopoulou G, et al. The effect of subconjunctival ranibizumab on primary pterygium: a pilot study. Cornea. 2010;29:1373-1379.
28. Mansour AM. Treatment of inflamed pterygia or residual pterygial bed. Br J Ophthalmol. 2009;93:864-865.
29. Finger PT, Chin KJ. Refractory squamous cell carcinoma of the conjunctiva treated with subconjunctival ranibizumab (Lucentis): a two-year study. Ophthal Plast Reconstr Surg. 2012;28:85-89.
30. Teng CC, Chin KJ. Subconjunctival ranibizumab for squamous cell carcinoma of the conjunctiva with corneal extension. Br J Ophthalmol. 2009;93:837-838.
31. Schmidt-Erfurth U. Clinical safety of ranibizumab in age-related macular degeneration. Expert Opin Drug Saf. 2010;9:149-165.
32. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (AvastinTM) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695. e1-15.
33. Dastjerdi MH, Sadrai Z, Saban DR, et al. Corneal penetration of topical and subconjunctival bevacizumab. Invest Ophthalmol Vis Sci. 2011;52: 8718-8723.